ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A gynecologic oncologic group study

H. D. Homesley, J. A. Blessing, J. Conroy, Kenneth D Hatch, P. J. DiSaia, L. B. Twiggs

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Twenty-seven patients with advanced adenocarcinoma of the endometrium were accessioned into this Phase II study evaluating the efficacy of ICRF-159 (razoxane) as second-line chemotherapy between February 1981 and September 1983. One patient was ineligible because of an undocumented primary. One patient was inevaluable because of concurrent use of adjunctive therapy and one patient had an inadequate trial. Twenty-four evaluable patients with measurable disease were given ICRF-159 orally at a starting dose of 1.5 g/m2 weekly until response could be determined. Grade 4 hematologic adverse effects were the only significant toxicity. There was no evidence of tumor response in any of the patients. Fourteen patients had stable disease and 10 had progressive disease. No activity was noted in advanced adenocarcinoma of the endometrium with ICRF-159 administered in the above dose and schedule.

Original languageEnglish (US)
Pages (from-to)15-17
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume9
Issue number1
Publication statusPublished - 1986
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this